Published in Br J Cancer on October 01, 1998
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol (1993) 5.65
Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst (1970) 4.88
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
B70 antigen is a second ligand for CTLA-4 and CD28. Nature (1993) 3.57
Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med (1991) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol (1979) 2.80
CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med (1992) 2.70
Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci U S A (1992) 2.56
Retracted Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. Nature (1994) 2.43
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93
CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med (1993) 1.93
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85
Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1) Immunity (1996) 1.69
Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human gamma 1. Immunology (1993) 1.54
A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med (1995) 1.44
T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med (1994) 1.43
Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res (1994) 1.27
In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol (1983) 1.26
Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer (1997) 1.20
In vivo natural reactivity of mice against tumor cells. Int J Cancer (1980) 1.16
A cell line from an induced carcinoma of mouse rectum. J Pathol (1978) 1.16
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med (1996) 1.13
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol (1996) 1.09
Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res (1994) 1.08
Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther (1994) 1.08
In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res (1993) 1.04
Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J Immunol (1997) 0.98
Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol (1995) 0.87
Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol (1995) 0.87
Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood (1996) 0.86
Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther (1996) 0.83
Allogeneic lymphocyte responses to B7-1 expressing human cancer cell lines. J Surg Res (1996) 0.83
B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther (1995) 0.82
Upregulation of B7 molecules by the Epstein-Barr virus enhances susceptibility to lysis by a human NK-like cell line. Cell Immunol (1995) 0.78
Immunotherapy I: Cyclosine gene transfer strategies. Cancer Metastasis Rev (1996) 0.77
Biological diversity in metastatic neoplasms: origins and implications. Science (1982) 3.95
A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer (1987) 3.80
Simulation technology for health care professional skills training and assessment. JAMA (1999) 3.49
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res (2001) 3.48
The biology of cancer invasion and metastasis. Adv Cancer Res (1978) 2.94
Paraquat poisoning. Lancet (1998) 2.89
Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. J Virol (1992) 2.80
Early onset of breast cancer in a group of British black women. Br J Cancer (2008) 2.47
The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol (1979) 2.42
In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res (1980) 2.40
Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res (1984) 2.13
Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med (1998) 2.12
A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst (1984) 2.08
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
BEME Guide No. 1: Best Evidence Medical Education. Med Teach (1999) 2.01
Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res (1980) 1.97
E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol (1993) 1.89
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther (2008) 1.88
Mortality and unemployment: A critique of Brenner's time-series analysis. Lancet (1981) 1.74
Pathways to care and ethnicity. 1: Sample characteristics and compulsory admission. Report from the AESOP study. Br J Psychiatry (2005) 1.70
Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer (2001) 1.64
Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J Pathol (2005) 1.61
Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol (1992) 1.61
Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol (1999) 1.60
Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res (1990) 1.51
Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res (1993) 1.50
Understanding the excess of psychosis among the African-Caribbean population in England. Review of current hypotheses. Br J Psychiatry Suppl (2001) 1.49
The varying impact of type, timing and frequency of exposure to childhood adversity on its association with adult psychotic disorder. Psychol Med (2010) 1.49
Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev (2010) 1.46
Gene transfer therapy in cancer. Br J Surg (1993) 1.43
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther (2009) 1.40
The first contact of patients with schizophrenia with psychiatric services: social factors and pathways to care in a multi-ethnic population. Psychol Med (1999) 1.40
An international virtual medical school (IVIMEDS): the future for medical education? Med Teach (2002) 1.38
Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer. Br J Cancer (1986) 1.36
Retroviral pseudotypes produced by rescue of a Moloney murine leukemia virus vector by C-type, but not D-type, retroviruses. Virology (1992) 1.34
Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J Virol (1997) 1.34
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 1.34
Cumulative social disadvantage, ethnicity and first-episode psychosis: a case-control study. Psychol Med (2008) 1.32
Colocalization of kindlin-1, kindlin-2, and migfilin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome. J Invest Dermatol (2008) 1.29
Ethnicity, social disadvantage and psychotic-like experiences in a healthy population based sample. Acta Psychiatr Scand (2008) 1.29
Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res (1994) 1.27
Combining dimensional and categorical representation of psychosis: the way forward for DSM-V and ICD-11? Psychol Med (2009) 1.27
Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer (1995) 1.26
'Seed and soil' revisited: mechanisms of site-specific metastasis. Cancer Metastasis Rev (1982) 1.25
Effect of sulfonation on the cell and tissue distribution of the photosensitizer aluminum phthalocyanine. Cancer Res (1990) 1.24
AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer (2001) 1.24
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res (2000) 1.24
Mechanisms of tumour metastasis. Eur J Cancer (1998) 1.22
Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol (2001) 1.18
Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp (1998) 1.18
Pathways to care and ethnicity. 2: Source of referral and help-seeking. Report from the AESOP study. Br J Psychiatry (2005) 1.17
Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res (1991) 1.16
Tissue uptake, distribution, and potency of the photoactivatable dye chloroaluminum sulfonated phthalocyanine in mice bearing transplantable tumors. Cancer Res (1988) 1.15
Encapsidation studies of poliovirus subgenomic replicons. J Gen Virol (1998) 1.15
The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J Biol Chem (2000) 1.14
Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst (1985) 1.14
Use of charge coupled device camera for imaging of intracellular phthalocyanines. Photochem Photobiol (1989) 1.13
Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin. J Cell Sci (1995) 1.13
Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells. Gut (2008) 1.12
Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab (2001) 1.11
Biological and experimental consequences of the zonal composition of solid tumors. Cancer Res (1981) 1.10
Mechanisms of metastasis. Crit Rev Oncol Hematol (1997) 1.09
Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res (2000) 1.09
A proposed architecture for lecithin cholesterol acyl transferase (LCAT): identification of the catalytic triad and molecular modeling. Protein Sci (1998) 1.09
Effectiveness of a computer-based system to teach bedside cardiology. Acad Med (1999) 1.09
Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer (1998) 1.08
Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther (2012) 1.08
Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res (1996) 1.07
Integrin expression in human melanoma cell lines: heterogeneity of vitronectin receptor composition and function. Int J Cancer (1991) 1.06
The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci (1998) 1.06
The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. J Cell Sci (1999) 1.06
Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol (2001) 1.06
Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat [corrected]. Hum Mol Genet (1994) 1.05
In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res (1993) 1.04
Heat shock proteins refine the danger theory. Immunology (2000) 1.04
The implications of tumor heterogeneity for studies on the biology of cancer metastasis. Biochim Biophys Acta (1981) 1.04
Cell surface properties of B16 melanoma variants with differing metastatic potential. Cancer Res (1980) 1.04
Genomic organization and complete sequence of the human gene encoding the beta-subunit of the cGMP phosphodiesterase and its localisation to 4p 16.3. Nucleic Acids Res (1991) 1.03
Mononuclear phagocyte adherence in the presence of laminin. A possible marker of cellular differentiation. Exp Cell Res (1983) 1.01
Attributing negative intent to wife behavior: the attributions of maritally violent versus nonviolent men. J Abnorm Psychol (1993) 1.01
Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin Cancer Res (2000) 1.00
alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J Invest Dermatol (2001) 1.00
International inter- and intrahospital patient spread of a multiple antibiotic-resistant strain of Klebsiella pneumoniae. J Infect Dis (1995) 0.99
Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. Cancer Res (1981) 0.99
Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. Cancer Res (1991) 0.98
Metastasis and angiogenesis. Acta Oncol (1990) 0.98
Factors influencing blood supply in wound granuloma quantitated by a new in vivo technique. Cancer Res (1989) 0.98
The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol (1996) 0.97
Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res (1981) 0.97
Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res (2000) 0.97
The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol (2001) 0.97
Identification of genes controlling metastatic behaviour. Br J Cancer (1991) 0.96
Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res (1999) 0.96
Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer (2001) 0.95
The effectiveness of immediate feedback during the objective structured clinical examination. Med Educ (1989) 0.95
The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes. Int J Radiat Oncol Biol Phys (2001) 0.95
Characterization of the plasma-membrane calcium pump from Trypanosoma cruzi. Biochem J (1995) 0.94
Induction of tumorigenicity and lack of in vitro growth requirement for 12-O-tetradecanoylphorbol-13-acetate by transfection of murine melanocytes with v-Ha-ras. Cancer Res (1989) 0.94